Connect Biopharma Shares Owned By Institutions vs. Shares Outstanding

CNTB Stock  USD 1.01  0.06  6.32%   
Based on the key profitability measurements obtained from Connect Biopharma's financial statements, Connect Biopharma Holdings may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess Connect Biopharma's ability to earn profits and add value for shareholders. At present, Connect Biopharma's PTB Ratio is projected to increase significantly based on the last few years of reporting. The current year's PB Ratio is expected to grow to 0.68, whereas Book Value Per Share is forecasted to decline to 1.00.
For Connect Biopharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Connect Biopharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Connect Biopharma Holdings utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Connect Biopharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Connect Biopharma Holdings over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Connect Biopharma. If investors know Connect will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Connect Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.39)
Revenue Per Share
0.438
Return On Assets
(0.12)
Return On Equity
(0.18)
The market value of Connect Biopharma is measured differently than its book value, which is the value of Connect that is recorded on the company's balance sheet. Investors also form their own opinion of Connect Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Connect Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Connect Biopharma's market value can be influenced by many factors that don't directly affect Connect Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Connect Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Connect Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Connect Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Connect Biopharma Shares Outstanding vs. Shares Owned By Institutions Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Connect Biopharma's current stock value. Our valuation model uses many indicators to compare Connect Biopharma value to that of its competitors to determine the firm's financial worth.
Connect Biopharma Holdings is rated below average in shares owned by institutions category among its peers. It is rated fourth in shares outstanding category among its peers creating about  1,243,899  of Shares Outstanding per Shares Owned By Institutions. As of December 25, 2024, Common Stock Shares Outstanding is expected to decline to about 43.5 M. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Connect Biopharma's earnings, one of the primary drivers of an investment's value.

Connect Shares Outstanding vs. Shares Owned By Institutions

Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.

Connect Biopharma

Shares Held by Institutions

 = 

Funds and Banks

+

Firms

 = 
44.42 %
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.

Connect Biopharma

Shares Outstanding

 = 

Public Shares

-

Repurchased

 = 
55.25 M
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.

Connect Shares Outstanding Comparison

Connect Biopharma is currently under evaluation in shares outstanding category among its peers.

Connect Biopharma Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Connect Biopharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Connect Biopharma will eventually generate negative long term returns. The profitability progress is the general direction of Connect Biopharma's change in net profit over the period of time. It can combine multiple indicators of Connect Biopharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income11.9 M12.4 M
Net Loss-1.2 B-1.1 B
Net Interest Income2.7 M2.8 M
Interest Income2.7 M3.5 M
Operating Income-62.1 M-65.2 M
Net Loss-59.5 M-62.5 M
Income Before Tax-59.4 M-62.4 M
Total Other Income Expense Net2.7 M2.8 M
Net Loss-59.4 M-62.4 M
Income Tax Expense120 K126 K
Change To Netincome847.5 M889.9 M
Net Loss(1.08)(1.13)
Income Quality 0.81  0.46 
Net Income Per E B T 1.00  0.80 

Connect Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Connect Biopharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Connect Biopharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Connect Biopharma's important profitability drivers and their relationship over time.

Learn to be your own money manager

Our tools can tell you how much better you can do entering a position in Connect Biopharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Earnings Calls Now

   

Earnings Calls

Check upcoming earnings announcements updated hourly across public exchanges
All  Next Launch Module

Use Investing Themes to Complement your Connect Biopharma position

In addition to having Connect Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Theme ETFs Thematic Idea Now

Theme ETFs
Theme ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Theme ETFs theme has 484 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Theme ETFs Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Connect Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Connect Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Connect Biopharma Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Connect Biopharma Holdings Stock:
Check out Trending Equities.
You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
To fully project Connect Biopharma's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Connect Biopharma at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Connect Biopharma's income statement, its balance sheet, and the statement of cash flows.
Potential Connect Biopharma investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Connect Biopharma investors may work on each financial statement separately, they are all related. The changes in Connect Biopharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Connect Biopharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.